A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration

Trial Profile

A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Aflibercept/rinucumab (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms CAPELLA
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 16 Feb 2017 Status changed from active, no longer recruiting to discontinued.
    • 30 Sep 2016 Primary endpoint (Change in Best corrected visual acuity (BCVA)) has not been met, according to a Regeneraon Pharmaceuticals media release.
    • 19 Aug 2016 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top